GlassScriptPhysician profile
Christopher Alexander Jimenez
NPI 1730509068
$24,911.67
in general payments reported to CMS, 2019-2025
70 companies · $4,953 in 2025
The $4,953 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $1,747 · 2021: $3,918 · 2022: $3,879 · 2023: $4,390 · 2024: $5,363 · 2025: $4,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,568.45 |
| Education | $137.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,142.40 | 2021-2025 | |
| Ucb, INC. | $2,844.56 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $1,158.90 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $1,143.79 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Teva Pharmaceuticals USA, INC. | $1,060.82 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mallinckrodt Hospital Products INC. | $975.65 | 2020-2025 | Acthar |
| Pfizer INC. | $950.26 | 2021-2025 | |
| Sk Life Science, INC. | $844.60 | 2020-2025 | |
| Eisai INC. | $831.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $711.17 | 2019-2025 | |
| Csl Behring | $704.07 | 2019-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $678.08 | 2019-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $644.30 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $554.40 | 2019-2025 | Uplizna, Aimovig |
| Otsuka America Pharmaceutical, INC. | $549.08 | 2023-2025 | Rexulti, Nuedexta |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $541.25 | 2021-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $534.12 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $531.69 | 2020-2025 | Rexulti, Vyepti |
| Amneal Pharmaceuticals LLC | $476.98 | 2019-2025 | Rytary, Crexont, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $388.24 | 2021-2025 | Hyqvia, Gammagard |
| Adamas Pharmaceuticals, INC. | $386.81 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $356.35 | 2023-2024 | Ztlido |
| Allergan, INC. | $332.07 | 2019-2022 | |
| Kyowa Kirin, INC. | $314.25 | 2019-2024 | Nourianz |
| Emd Serono, INC. | $307.90 | 2020-2025 | Mavenclad |
| Almatica Pharma LLC | $295.23 | 2021-2022 | |
| Tg Therapeutics, INC. | $273.52 | 2023-2025 | |
| Acorda Therapeutics, INC | $273.34 | 2019-2024 | Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $272.90 | 2021 | |
| Tanabe Pharma America, INC. | $246.15 | 2020-2024 | |
| Genzyme Corporation | $238.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $191.96 | 2021-2025 | Wainua |
| Mdd US Operations, LLC | $162.77 | 2022-2025 | Apokyn |
| Biohaven Pharmaceutical Holding Company LTD. | $126.18 | 2022 | |
| Banner Life Sciences, LLC | $124.71 | 2022-2024 | |
| Aprecia Pharmaceuticals, LLC | $123.19 | 2022-2023 | Spritam |
| Upsher-Smith Laboratories LLC | $122.61 | 2019-2023 | |
| Boston Scientific Corporation | $122.20 | 2019-2025 | Watchman Flx |
| Merz Pharmaceuticals, LLC | $121.96 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Avion Pharmaceuticals | $120.31 | 2022-2023 | Dhivy |
| Alexion Pharmaceuticals, INC. | $114.29 | 2020-2025 | Ultomiris, Soliris |
| Abbott Laboratories | $84.81 | 2022-2025 | Infinity, Eterna |
| Avanir Pharmaceuticals, INC. | $84.19 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $73.55 | 2021-2022 | |
| Livanova USA, INC. | $72.79 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $71.06 | 2025 | |
| Cycle Pharmaceuticals INC | $62.15 | 2025 | Tascenso Odt, Bafiertam |
| Alfasigma USA, INC. | $61.21 | 2020-2022 | |
| Axsome Therapeutics, INC. | $53.42 | 2025 | Symbravo |
| Genentech USA, INC. | $46.77 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Arbor Pharmaceuticals, INC. | $36.06 | 2022 | |
| Ani Pharmaceuticals, INC. | $33.78 | 2025 | Purified Cortrophin Gel |
| C2n Diagnostics, LLC | $33.72 | 2025 | Precivityad2 |
| Vanda Pharmaceuticals INC. | $31.09 | 2023 | Fanapt, Hetlioz |
| Life Molecular Imaging LTD | $27.52 | 2024 | Neuraceq |
| Alnylam Pharmaceuticals INC. | $24.91 | 2023 | Onpattro |
| Octapharma USA, INC. | $24.75 | 2025 | Panzyga |
| Xeris Pharmaceuticals, INC. | $21.91 | 2025 | Keveyis |
| Azurity Pharmaceuticals, INC. | $20.80 | 2023 | Horizant |
| Impel Pharmaceuticals INC. | $20.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Insightec,INC | $17.64 | 2024 | Exablate |
| Cala Health, INC. | $17.15 | 2022 | |
| Hyperfine Operations, INC. | $16.93 | 2025 | Swoop |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.11 | 2024 | Caplyta |
| Currax Pharmaceuticals LLC | $15.03 | 2020 | |
| Nevro Corp. | $14.17 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.